Pregnancy in patients affected by axial-spondyloarthritis: a narrative review of disease activity and obstetric outcomes
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Objective. This review aims to summarize the most recent and updated data on pregnancy in patients with axial spondyloarthritis (axSpA), focusing on the recurrence of pregnancy-related complications, the disease activity throughout gestation and the postpartum, and the latest indications for the treatments of future mothers.
Methods. We have conducted a narrative review with an online literature search on Medline and PubMed. We selected only studies written in English published until January 2024, including observational and retrospective studies, meta-analyses, and systematic reviews.
Results. Proper preconception counseling and maternal-fetal monitoring are necessary to ensure the best outcome for both the mother and her baby. Despite the limited and conflicting evidence about the prevalence of adverse pregnancy outcomes in women with axSpA compared to healthy controls, primary findings demonstrate an increased risk of preterm delivery (PTD), low birth weight (LBW), and elective cesarean section (CS). Concerning disease activity, data suggests that 25-80% of women with ankylosing spondylitis experience disease flares during pregnancy, particularly around 20 weeks of gestation. On the contrary, the data on the postpartum disease flare are heterogeneous. The use of biological drugs in pregnancy is safe and effective in controlling disease activity.
Conclusions. Data on pregnancy outcomes in patients with axSpA are scarce and discordant. Probably the difference in maternal disease classification, the evolution of treatment indications, and the differences emerging from study designs can account for these discrepancies. The main evidence shows an increased risk of PTD, LBW, and elective CS (although the latter may reflect cultural influences rather than medical needs due to axSpA itself). The majority of drugs used to treat axSpA, including TNFi, are safe in pregnancy without harming mothers or fetuses. Further data is needed to clarify many controversial aspects in this area.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- T. Borges, J. Vilaça, S. Ferreira, I. Chora, S. Silva, C. Dias, Systemic sclerosis sine scleroderma: a case report of anterior uveitis , Reumatismo: Vol. 67 No. 1 (2015)
- W. Grassi, R. De Angelis, Clinical features of gout , Reumatismo: Vol. 63 No. 4 (2011): Special issue • Microcrystalline Arthritis
- M. Di Gangi, R. Foti, R. Leonardi, C. Leonetti, P. Castellino, Recurrent new-onset uveitis in a patient with rheumatoid arthritis during anti-TNFα treatment , Reumatismo: Vol. 59 No. 2 (2007)
- S. Muller, S. Hider, T. Helliwell, R. Partington, C. Mallen, The real evidence for polymyalgia rheumatica as a paraneoplastic syndrome , Reumatismo: Vol. 70 No. 1 (2018): Monographic issue on Polymyalgia Rheumatica
- D. Biscontini, E. Bartoloni Bocci, R. Gerli, Analysis of foot structural damage in rheumatoid arthritis: clinical evaluation by validated measures and serological correlations , Reumatismo: Vol. 61 No. 1 (2009)
- E. Catarsi, M. Doveri, A. Tavoni, Bosentan and sildenafil: successful treatment in a sclerodermic patient with refractory ulcers , Reumatismo: Vol. 65 No. 2 (2013)
- M. Polastri, L. Di Marco, S. Cantagalli, M. Di Eusanio, Octogenarian with an untreated femoral neck fracture: upright position during the postoperative course after aortic valve replacement , Reumatismo: Vol. 67 No. 1 (2015)
- H.K. Aggarwal, D. Jain, A. Mittal, A. Rao, R.K. Yadav, P. Jain, Systemic lupus erythematosus presenting as fulminant lupus pneumonitis: a rare case report , Reumatismo: Vol. 68 No. 1 (2016)
- F. Gediz, A.F. Yilmaz, B. Payzin, T. Yuksel, A.O. Calli, S. Kobak, Development of Hodgkin lymphoma in a patient with sarcoidosis , Reumatismo: Vol. 69 No. 2 (2017)
- H. Semiz, M. Yalcin, S. Kobak, Coexistence of sarcoidosis and Hashimoto thyroiditis , Reumatismo: Vol. 70 No. 2 (2018)
<< < 11 12 13 14 15 16 17 18 19 20 > >>
You may also start an advanced similarity search for this article.